Aurobindo Pharma completes acquisition of US-based Lannett Company

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.3%Reaction day

₹1538.30

prior close

₹1571.90

announcement price

In-mkt

timing

Nifty Midcap 150market+0.4%+1.9% vs market

Pharmaceuticals peers, median of 165sector+0.8%+1.5% vs sector

On the reaction day the stock moved 1.9 pts more than Nifty Midcap 150 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.4

10m

+0.3

15m

+0.0

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.3+0.4+1.9+0.8+1.5

Next day

+0.8+0.6+0.1+0.3+0.5

+1.6+1.1+0.5+0.8+0.8

+5.1+0.9+4.2+1.2+3.9

+3.6+1.3+2.4+0.6+3.0

+2.9+1.0+1.9+0.1+2.8

+2.9+0.8+2.1+0.6+2.3

15d

+3.0+2.2+0.8+1.7+1.2

+2.5+1.6+1.0-0.5+3.0

+11.6+3.8+7.8+2.7+8.9

+8.7-3.6+12.3+3.2+5.5

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aurobindo Pharma's US arm APUSA has completed the acquisition of US-based Lannett Company Inc. on June 29, 2026, after receiving US FTC approval on June 18. Lannett will operate as Lannett Company LLC, becoming a wholly owned subsidiary of APUSA. Over 400 Lannett employees will join APUSA. Integration begins immediately, focused on uninterrupted medicine supply and long-term value for stakeholders.

Likely market impact

Strengthens Aurobindo's US generics footprint with expanded product portfolio and operational scale. Positive for long-term growth.